Teva Pharmaceutical Industries (TEVA) Earnings Date & Reports

Key Takeaways

• Teva reported third-quarter 2026 revenue of $4.4 billion, down about 2% year over year but above the roughly $4.2 billion consensus estimate.
• Non-GAAP (non-GAAP = excluding one-time items) earnings per share came in at $0.86, a 10% increase from $0.78 a year earlier and well above the $0.72 analyst consensus.
• Growth was driven by branded medicines, with AUSTEDO up 21% to $751 million, AJOVY up 61% to $269 million, and UZEDY nearly doubling to $85 million.
• Generic drug revenue fell about 16% in the quarter, largely reflecting a lower contribution from generic REVLIMID.
• Teva raised its full-year 2026 outlook for the second consecutive quarter, lifting revenue guidance to $16.7–$17.0 billion.
• For additional context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast.
• Discover actionable market ideas and automated strategies by exploring Trending AI Robots.

Earnings Context and Why It Matters

Teva Pharmaceutical Industries' third-quarter 2026 report marks a key checkpoint in the company's "Pivot to Growth" strategy. After years of decline, Teva has strung together a long run of consecutive growth quarters, but the latest period reveals a more nuanced picture: branded franchises are expanding rapidly while the generics business, once the company's backbone, is shrinking. Investors watch this report closely because it tests whether margin expansion and innovative-product momentum can offset fading generic revenue. With the company transitioning toward a biopharma model, this quarter's results and raised guidance offer a clearer read on whether that transformation is translating into durable profitability and improving balance-sheet strength.

Reported Results

For the third quarter of 2026, Teva reported total revenue of $4.4 billion, a decline of roughly 2% from the prior-year period but comfortably above the consensus estimate of about $4.2 billion. Non-GAAP earnings per share reached $0.86, up 10% from $0.78 in the same quarter a year earlier and well ahead of the $0.72 analysts had expected. GAAP (GAAP = Generally Accepted Accounting Principles) net profit was $233 million, down 46% year over year, while non-GAAP net profit rose 11.3% to approximately $1 billion.

Gross margin expanded to 58.7%, an improvement of 345 basis points, and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) grew 7%. The innovative portfolio rose 33% year over year, led by AUSTEDO ($751 million, up 21%), AJOVY ($269 million, up 61%), and UZEDY ($85 million, up 96%). Generics revenue fell 16%, primarily due to a lower contribution from generic REVLIMID. Management raised 2026 revenue guidance to $16.7–$17.0 billion and set adjusted EPS (earnings per share) guidance at $1.92–$2.11.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following names like Teva, it offers a structured way to compare peers across the specialty and generic pharmaceutical space and identify emerging signals at a glance.

Market Reaction and Investor Sentiment

Investors responded positively to the report, with Teva's New York-listed shares rising around 5.8% to approximately $43 in morning trading following the release. The combination of an earnings beat, a revenue beat, and a second consecutive guidance increase reinforced confidence that the company's branded-drug strategy is working. Sentiment was further supported by management's confirmation of momentum across AUSTEDO, AJOVY, and UZEDY, which helped offset investor concerns about the structural decline in generics. The company's continued deleveraging and margin expansion also contributed to a more favorable reaction, though the decline in GAAP net profit and the generics headwind remain areas investors are watching closely.

Forward Outlook and Key Factors to Monitor

Following this earnings event, several factors will shape Teva's trajectory. First, investors should monitor the branded growth engines, particularly AUSTEDO, AJOVY, and UZEDY, whose raised outlooks now anchor the company's near-term growth story. The pace at which these franchises convert strong demand into revenue will be a central driver of performance.

Second, the generics business remains a key swing factor. While the latest decline was largely tied to generic REVLIMID, sustained weakness in this segment could pressure overall top-line growth. Conversely, Teva's biosimilar pipeline represents a potential offset, with management signaling it may reach its 2027 biosimilar revenue target ahead of schedule.

Finally, investors should track margin progression and balance-sheet improvements, as the company continues to prioritize a 30% non-GAAP operating margin target and further debt reduction. Newer launches such as the schizophrenia treatment Weltruza, while not expected to contribute meaningful revenue until later, will be an important catalyst to watch as 2027 and 2028 approach.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations